Welcome to our dedicated page for Mediwound SEC filings (Ticker: MDWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MediWound Ltd. SEC filings document a foreign private issuer focused on enzymatic therapeutics for tissue repair. Its Form 20-F annual reports and Form 6-K current reports cover operating and financial results, clinical and regulatory disclosures for NexoBrid and EscharEx, material-event updates, and registration-statement information tied to Form S-8 and Form F-3 filings.
The company’s filings also record governance and capital-structure matters, including annual and extraordinary shareholder meeting materials, proxy statements, board elections, ordinary share voting mechanics, and share incentive plan approvals under Israeli corporate governance requirements. Other disclosures address distribution and procurement-related developments for NexoBrid, risk factors, material agreements, and shareholder voting results.
MediWound Ltd. director Nachum Shamir reported buying 6,000 ordinary shares in the open market. The Form 4 shows two purchase transactions on June 3, 2026, involving 5,825 shares at $14.00 per share and 175 shares at $13.975 per share.
Following these purchases, Shamir directly holds 49,990 ordinary shares. He also has 1,200 ordinary shares underlying RSUs that were granted on March 4, 2026 and vest in full one year after the grant date. In addition, he holds several stock option grants and Series A warrants over ordinary shares with exercise prices between $11.8850 and $18.5400, and Series A warrants exercisable at $13.4750 per share through November 28, 2026.
MediWound Ltd. director David Morton Fox reported open-market purchases of a total of 3,537 ordinary shares on June 1, 2026, at prices between $13.995 and $14.23 per share. Other rows in the filing reflect existing holdings only, with no transactions in those securities.
He also holds several equity incentives, including stock options over 6,250 ordinary shares at an exercise price of $17.6000 expiring on March 4, 2036, and Series A warrants over 6,534 ordinary shares at an exercise price of $13.4750 expiring on November 28, 2026. Footnotes state that certain RSUs and options granted on March 4, 2026 vest 100% on the one-year anniversary of that grant date.
MediWound Ltd. director Samuel Rubinstein reported a small open-market purchase of 150 Ordinary Shares of MediWound on May 29, 2026 at $14.33 per share. After this trade, he directly holds 2,993 Ordinary Shares and indirectly holds 525 Ordinary Shares through his spouse.
He also holds several stock option awards giving rights to buy additional Ordinary Shares at exercise prices between $9.64 and $18.54, with expirations from 2033 to 2036. Footnotes clarify that certain ordinary share and option holdings reflect previously granted RSUs and options included for informational purposes, with no transactions occurring in those rows.
MediWound Ltd. reported first quarter 2026 revenue of $1.5 million, down from $4.0 million in the first quarter of 2025, as it increased investment in its pipeline. The company reaffirmed full‑year 2026 revenue guidance of $24–26 million.
For the quarter ended March 31, 2026, MediWound recorded an operating loss of $8.0 million and a net loss of $3.0 million, compared with a net loss of $0.7 million a year earlier, driven mainly by higher research and development spending.
The global Phase III VALUE trial of EscharEx in venous leg ulcers is ongoing, with enrollment progressing more gradually than anticipated; an interim assessment and enrollment completion are expected by the end of the first quarter of 2027. For NexoBrid, a BARDA contract awarded to Vericel and other government and military initiatives are expected to support revenue growth in the second half of 2026.
As of March 31, 2026, MediWound held $44.6 million in cash, cash equivalents and short‑term bank deposits and reported Adjusted EBITDA of -$7.0 million for the quarter, reflecting continued operating losses as it advances late‑stage programs.
MEDIWOUND LTD reported a Schedule 13G filing showing T. Rowe Price Associates, Inc. holds 5.5% of common stock, amounting to 709,847 shares. The filer discloses sole voting power of 707,170 shares and sole dispositive power of 709,847 shares. The filing includes a statement denying beneficial ownership. Signature date: 05/15/2026.
MediWound Ltd. reported the results of its 2026 annual general meeting of shareholders. A quorum of 6,208,465 ordinary shares, representing 48.3% of outstanding shares as of March 31, 2026, was present in person or by proxy. Shareholders approved all proposals, including the election of five directors, each receiving approximately 99% of votes cast. Proposal 3 was also approved by the required special majority of shareholders who were not controlling shareholders and lacked a “personal interest” under Israeli Companies Law. The report and its exhibit are incorporated by reference into MediWound’s existing Form S-8 and Form F-3 registration statements.
MediWound Ltd. reports that its North America distributor Vericel has been awarded a ten-year BARDA contract valued at up to $197 million related to burn treatment product NexoBrid.
According to Vericel, the contract covers NexoBrid procurement for the U.S. Strategic National Stockpile, a Vendor Managed Inventory system, development of a next generation formulation, an additional indication such as blast trauma injuries, and design and validation of a potential U.S.-based manufacturing facility.
Vericel reported that the base period totals $35 million, including about $10 million over the next 12 months for initial NexoBrid procurement and VMI establishment. MediWound notes these statements are based on Vericel’s reports and highlights typical clinical, regulatory, commercial and BARDA-related uncertainties.
MediWound Ltd. has called its 2026 annual general meeting of shareholders for May 6, 2026 in New York. Investors will vote on re-electing five directors, reappointing Somekh Chaikin (KPMG member firm) as independent auditor for 2026, and approving an annual cash bonus of approximately $206,000 for CEO Ofer Gonen based on 2025 performance.
The company will also present its audited consolidated financial statements for the year ended December 31, 2025, as previously filed in its Form 20-F. Shareholders of record at the close of business on March 31, 2026 are entitled to vote, with one vote per ordinary share.
MediWound Ltd. director Vickie Rae Driver filed an initial ownership report detailing her equity interests in the company. She directly holds ordinary shares, including shares underlying restricted stock units granted on March 4, 2026 that vest in full one year after the grant date.
She also holds several stock option awards to buy ordinary shares at exercise prices ranging from 11.8850 to 37.5200 per share, with expiration dates between 2030 and 2036. This filing records existing holdings and does not show any new purchases or sales.
MediWound Ltd. Chief Financial Officer Hana Luxenburg Kalfon filed an initial Form 3 reporting her equity holdings in the company. She directly holds stock options over 39,000, 32,681, 24,000 and 26,000 ordinary shares at exercise prices of $11.9000, $12.7290, $18.5400 and $17.6000, expiring between May 2033 and March 2036. She also holds 4,085, 3,000 and 3,200 ordinary shares underlying restricted share units granted in 2024, 2025 and 2026, which vest 25% after one year and then 6.25% quarterly over four years.